Literature DB >> 2108033

Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance.

P Angeli1, A Gatta, L Caregaro, F Menon, D Sacerdoti, C Merkel, M Rondana, R de Toni, A Ruol.   

Abstract

Renal tubular sodium handling was evaluated in 27 non-azotemic cirrhotic patients with ascites and positive sodium balance and in 17 controls after at least 5 days of a constant sodium intake using the lithium clearance as an index of fluid delivery to the distal tubule. Plasma renin activity and plasma aldosterone were also evaluated. Sodium fractional excretion, filtered sodium load, absolute sodium distal delivery, lithium fractional excretion and absolute distal sodium reabsorption were significantly lower in cirrhotics than in controls (0.58 +/- 0.11 vs. 1.29 +/- 0.12%, P less than 0.001; 12529 +/- 677 vs. 15707 +/- 796 microEq min-1 1.73 m-2 BSA, P less than 0.005; 2384 +/- 135.2 vs. 3685 +/- 219.3 microEq min-1 1.73 m-2 BSA, P less than 0.001; 19.5 +/- 1.0 vs. 24.2 +/- 1.3%, P less than 0.01; 2299 +/- 127 vs. 3485 +/- 214 microEq min-1 1.73 m-2 BSA, P less than 0.001, respectively). A correlation was found between lithium clearance and sodium clearance only in cirrhotic patients (r = 0.62; P less than 0.01). Distal sodium reabsorption evaluated as a per cent of filtered sodium load was lower in cirrhotics than in controls (19.1 +/- 1.0 vs. 22.4 +/- 1.2%, P less than 0.05) while distal sodium reabsorption evaluated as a per cent of sodium distal delivery was higher in cirrhotics than in controls (96.7 +/- 0.4 vs. 94.4 +/- 0.5%, P less than 0.005).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108033     DOI: 10.1111/j.1365-2362.1990.tb01800.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  19 in total

1.  [6 years of the International Union of Societies of Immunology. Presidential report (Brighton 1974)].

Authors:  B Cinader
Journal:  Medicina (B Aires)       Date:  1975 Jul-Aug       Impact factor: 0.653

2.  Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE.

Authors:  D Sacerdoti; M Balazy; P Angeli; A Gatta; J C McGiff
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  Acute renal injury after partial hepatectomy.

Authors:  Luis Alberto Batista Peres; Luis Cesar Bredt; Raphael Flavio Fachini Cipriani
Journal:  World J Hepatol       Date:  2016-07-28

Review 4.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Incidence and risk factors for early renal dysfunction after liver transplantation.

Authors:  Patricia Wiesen; Paul B Massion; Jean Joris; Olivier Detry; Pierre Damas
Journal:  World J Transplant       Date:  2016-03-24

Review 6.  Management of ascites and hepatorenal syndrome.

Authors:  Salvatore Piano; Marta Tonon; Paolo Angeli
Journal:  Hepatol Int       Date:  2017-08-23       Impact factor: 6.047

7.  Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis.

Authors:  Carmen C Franz; Sabin Egger; Christa Born; Alexandra E Rätz Bravo; Stephan Krähenbühl
Journal:  Eur J Clin Pharmacol       Date:  2011-08-13       Impact factor: 2.953

Review 8.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  Acute kidney injury in patients with cirrhosis of liver: Clinical profile and predictors of outcome.

Authors:  Shiran Shetty; Shankar Prasad Nagaraju; Srinivas Shenoy; Ravindra Prabhu Attur; Dharshan Rangaswamy; Indu R Rao; Uday Venkat Mateti; Rajeevalochana Parthasarathy
Journal:  Indian J Gastroenterol       Date:  2018-07-17

Review 10.  KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2018-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.